NEWS & VIEWS

Global private equity and venture capital news and research

Posts Tagged ‘MPM Capital’

13 April 2015

MPM Capital nabs Flagship Ventures’ Sieczkiewicz for MD role

2cb320a US healthcare investor MPM Capital has appointed Gregory Sieczkiewicz to the role of managing director and chief counsel intellectual property, effective immediately.

29 August 2014

Venture capital-backed Rhythm files for Nasdaq IPO

nasdaq Venture capital-backed metabolic drug developer Rhythm has filed for an IPO on the Nasdaq exchange.

21 July 2014

NEA, Apple Tree, MPM Capital lead $32m Series B for drug company

capsule-1006559-m New Enterprise Associates, Apple Tree Partners and MPM Capital have helped nervous system disorder specialist Cerecor raise $32m in its Series B first tranche.

19 May 2014

US biopharma Proteon Therapeutics raises $45m Series D

US biopharmaceutical company Proteon Therapeutics has closed a $45m of Series D equity financing, including a $25m tranche to fully fund the first Phase 3 clinical study of its lead product.

18 November 2013

TriVascular raises $40m Series E from new and existing investors

Medical devices startup TriVascular, which is focused on endovascular aortic repair, has raised a $40m Series E round.

9 October 2013

Bay City Capital brings in ex-MPM Capital managing director Ashley Dombkowski

Ashley Dombkowski Bay City Capital Life sciences-focused venture firm Bay City Capital has hired ex-MPM Capital managing director Ashley Dombkowski.

27 August 2013

Syndax Pharmaceuticals raises $26.6m Series B round from healthcare VCs

US-based Syndax Pharmaceuticals has secured a $26.6m Series B financing from investors including healthcare-focused venture capital firms Domain Associates, MPM Capital, Forward Ventures and Russia’s RusnanoMedInvest.

7 August 2013

Corporate venture firms make larger investments than VC peers $

Corporate venture capital firms accounted for a quarter of all venture funding provided in the second quarter and invested significantly more than their peers on average, a study by CB Insights found.

26 July 2013

Venture capital-backed Conatus falls after raising $66m via IPO

Venture capital-backed biotech company Conatus Pharmaceuticals raised $66m via an IPO on the dipped more than 10 per cent in its first day of trading on the Nasdaq exchange after raising $66m via its IPO.

8 May 2013

Venture-backed biopharma Portola eyes $127m Nasdaq IPO

Venture-backed biopharmaceutical company Portola Pharmaceuticals is targeting $127m from its listing on Nasdaq.

Page 1 of 212

Legals & Terms of UsePrivacy Policy


AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2015